• Cell Divisions Refine Drosophila Tissue Boundaries

  2026-08-18

  A 2026 Development study shows that ectodermal cell divisions can both challenge and sharpen the mesectoderm–ectoderm boundary in the Drosophila embryo. By combining mathematical modelling, quantitative microscopy, laser ablation and cell tracking, the authors identify division-driven tissue fluidity as a previously unreported mechanism of boundary refinement.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-08-17

  A 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a suppressor of sorafenib resistance in hepatocellular carcinoma. The work connects HNF4A-AS1 to METTL3-dependent m6A modification of DECR1 mRNA, PUFA preservation, and ferroptosis, offering a mechanistic framework for studying lipid-metabolism-driven treatment failure.

• Streptavidin-HyperFluor 647: Applied Workflows

  2026-08-17

  Streptavidin-HyperFluor 647 supports sensitive far-red detection of biotinylated antibodies, nucleic acids, proteins, and proximity-labeling products across microscopy and flow cytometry. This guide shows when to use this Streptavidin fluorescent conjugate—and when the biotin-free BmTyr strategy from the reference study is the better experimental choice.

• Tacrolimus (FK506): From Target to Assay

  2026-08-16

  Tacrolimus (FK506) is more than a calcineurin inhibitor: it is a tool for testing immunophilin-dependent control of T-cell signaling. This article connects FKBP12–calcineurin pharmacology with genetic evidence from cyclosporine research to improve assay interpretation and experimental design.

• 3-Hydroxybutyrate (BHBA): From Ketosis to Neuroprotection

  2026-08-15

  3-hydroxybutyrate (BHBA) is more than a ketone fuel: it is a fatty acid β-oxidation metabolite, ketone body signaling molecule, and class I HDAC inhibitor with potential relevance to ferroptosis and ischemic neuroprotection. This translational guide interprets recent stroke research, proposes a validation strategy, and explains how defined BHBA perturbation can strengthen metabolic and epigenetic research programs.

• Bradford Protein Assay Kit: Practical Guide

  2026-08-14

  The Bradford Protein Assay Kit K4103 provides rapid protein concentration measurement from small-volume samples using Coomassie Brilliant Blue G-250 and BSA standards. It is suited to enzyme assays, protein purification, and molecular biology workflows, but results require control of buffer interference and should not be interpreted as a direct measure of protein identity, purity, or activity.

• Difloxacin HCl: From Gyrase to Translation

  2026-08-14

  Difloxacin HCl offers translational researchers a dual-use framework: bacterial DNA gyrase inhibition for antimicrobial susceptibility testing and a research path for multidrug resistance reversal. This article connects mechanism, assay design, product handling, and cross-domain interpretation without overstating evidence from mammalian cell-cycle research.

• Platelet Extravasation in Tumors: CXCR4 Control

  2026-08-13

  The reference study defines platelet transendothelial migration into tumors as a regulated process rather than a passive consequence of vascular leak. Its genetic, pharmacologic, and imaging data connect stromal CXCL12/CXCR4 signaling, FAK, PECAM-1, and distinct platelet granule pathways to tumor platelet infiltration, vascular integrity, and tumor growth.

• Isorhamnetin: PI3K/Akt Oocyte Assay Workflow

  2026-08-13

  Build a mechanism-led Isorhamnetin workflow for oocyte maturation, oxidative stress, apoptosis, and endoplasmic reticulum stress studies. The practical design combines concentration control, DMSO handling, polar body extrusion, ROS, and pathway-level readouts rather than treating this flavonoid as a nonspecific antioxidant.

• Minocycline HCl for EV Inflammation Workflows

  2026-08-12

  Use Minocycline HCl as a controlled antimicrobial or anti-inflammatory perturbation alongside scalable iMSC-derived extracellular vesicle assays. This workflow separates EV manufacturing from recipient-cell testing, helping researchers distinguish product consistency, inflammation control, and compound-specific effects.

• Renal K+ Channels in Septic Rat Hemodynamics

  2026-08-12

  The reference study examined how ATP-sensitive and calcium-activated potassium channels shape renal vascular responses during experimental sepsis, integrating isolated perfused-kidney experiments with in vivo renal blood-flow measurements. Its central finding is that channel blockade can unmask or intensify pressor-associated renal hypoperfusion, emphasizing that vasopressor responses in sepsis cannot be interpreted independently of vascular-bed-specific potassium-channel function.

• Doxycycline for 3D Mechanobiology Research

  2026-08-11

  Doxycycline combines tetracycline antibiotic activity with metalloproteinase inhibition, creating a useful perturbation tool for cancer, matrix-remodeling, and 3D cell studies. This guide translates new findings on rapid cell tumbling into practical assays while clearly separating established evidence from testable Doxycycline hypotheses.

• MFGE8–ANXA1/SMAD2/3 in Pancreatic Fibrosis

  2026-08-11

  This study links umbilical cord-derived mesenchymal stem cell extracellular vesicles to suppression of pancreatic fibrosis through an MFGE8-dependent ANXA1–SMAD2/3 pathway. Its progression from cell therapy to recombinant MFGE8 nanoparticles provides a mechanistic and translational framework for developing cell-free antifibrotic interventions in chronic pancreatitis.

• AMPK–p62 Feedback Amplifies NRF2 Defense Under Stress

  2026-08-10

  The 2024 Autophagy study identifies a double-positive feedback loop in which metabolic stress induces SQSTM1/p62, while AMPK activity reinforces p62 expression and phosphorylation. This coupling activates both AMPK and NFE2L2/NRF2 through distinct lysosomal mechanisms, offering a mechanistic explanation for stress adaptation in STK11/LKB1- and KEAP1-altered lung cancer models.

• Targeted Peptide Nanocarriers for Breast Cancer

  2026-08-08

  The reference study developed DT/Pep1, an acid-sensitive, deformable peptide nanocarrier that co-delivers doxorubicin and triptolide to breast cancer cells. Its combination of peptide targeting, deeper tumor penetration, prolonged intracellular retention, apoptosis, and immune activation improved antitumor performance in cellular and 4T1 mouse models.

8641 records 9/577 page Previous Next First page 上5页 678910 下5页 Last page